Catalyst Biosciences Inc (NASDAQ:CBIO) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus target price of $57.00 for the company and are predicting that the company will post ($1.30) EPS for the current quarter, according to Zacks. Zacks has also given Catalyst Biosciences an industry rank of 194 out of 265 based on the ratings given to related companies.
A number of research firms recently commented on CBIO. B. Riley set a $49.00 target price on shares of Catalyst Biosciences and gave the company a “buy” rating in a research report on Friday, February 9th. Chardan Capital increased their target price on shares of Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 9th. ValuEngine raised shares of Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Tuesday, January 2nd.
In other Catalyst Biosciences news, insider James E. Flynn sold 71,778 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $30.53, for a total transaction of $2,191,382.34. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder James E. Flynn sold 52,461 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $30.87, for a total transaction of $1,619,471.07. The disclosure for this sale can be found here. Corporate insiders own 5.00% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 32,621 shares in the last quarter. Ardsley Advisory Partners acquired a new position in Catalyst Biosciences during the 4th quarter valued at approximately $205,000. Dimensional Fund Advisors LP acquired a new position in Catalyst Biosciences during the 2nd quarter valued at approximately $372,000. Geode Capital Management LLC acquired a new position in Catalyst Biosciences during the 4th quarter valued at approximately $379,000. Finally, Raymond James & Associates acquired a new position in Catalyst Biosciences during the 4th quarter valued at approximately $585,000. Institutional investors and hedge funds own 26.48% of the company’s stock.
Catalyst Biosciences (CBIO) traded up $0.32 during trading hours on Friday, reaching $27.36. 143,277 shares of the company were exchanged, compared to its average volume of 486,978. Catalyst Biosciences has a 12 month low of $3.11 and a 12 month high of $37.00. The stock has a market capitalization of $297.69, a PE ratio of -2.89 and a beta of 2.58.
Catalyst Biosciences (NASDAQ:CBIO) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.41) by $0.45. Catalyst Biosciences had a negative net margin of 2,117.98% and a negative return on equity of 93.68%. The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.23 million. analysts expect that Catalyst Biosciences will post -4.16 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Zacks: Catalyst Biosciences Inc (CBIO) Given Consensus Recommendation of “Strong Buy” by Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/22/zacks-catalyst-biosciences-inc-cbio-given-consensus-recommendation-of-strong-buy-by-analysts.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.